Exact Sciences (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
39,000€
0,92%
Echtzeit-Aktienkurs Exact Sciences Corp.
Bid:
Ask:
Nachrichten zur Exact Sciences Corp. Aktie
Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
…
Exact Sciences (EXAS) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Cathie Wood Darling Could Pop On Its Next-Gen Colon Cancer Test
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…